Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04922021 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT04922021 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 58 participants.
The verdict
NCT04922021, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side effects are when compared with a placebo injection with no medical ingredient. The study will last up to 36 weeks for each participant. The study will include a treatment period of 16 weeks, during which the participants will receive the injections, followed by a period of 16 weeks without treatment with the main purpose of continuing safety evaluations. The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD. The participants will also be asked to answer questions about their AD symptoms and quality of life.
Interventions
- DRUG LEO 138559
- DRUG LEO 138559 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2022-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04922021
The ClinicalTrials.gov registry entry for NCT04922021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LEO 138559 is the first listed.
NCT04922021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04922021 about?
NCT04922021 is a clinical study titled "An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.". This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side effects are when compared with a placebo injection with no medical ingre...
What is the current status of trial NCT04922021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2021-07-14. Estimated completion is 2022-09-26.
What interventions are being tested in trial NCT04922021?
The interventions under investigation include: LEO 138559 (DRUG), LEO 138559 placebo (DRUG).
Who is sponsoring clinical trial NCT04922021?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.